• 作者：Patricia Manzano-Gayosso^a ; ^b ; ^{angelesmg@liceaga.facmed.unam.mx} ; Luis Javier Mé ; ndez-Tovar^c ; Roberto Arenas^d ; Francisca Hern&#225 ; ndez-Hern&#225 ; ndez^a ; Blanca Mill&#225 ; n-Chiu^a ; Josep M. Torres-Rodrí ; guez^e ; Elda Corté ; s-Gonz&#225 ; lez^a ; Ramó ; n Fern&#225 ; ndez^d ; Rubé ; n Ló ; pez-Martí ; nez^a
• 关键词：Onicomicosis ; Candida albicans ; Candida parapsilosis ; Sensibilidad antifú ; ngica ; Itraconazol ; Fluconazol
• 刊名：Revista Iberoamericana de Micolog¨ªa
• 出版年：2011
• 出版时间：January-March 2011
• 年：2011
• 卷：28
• 期：1
• 页码：32-35
• 全文大小：109 K

Background

Yeasts represent the second cause of nail fungal infection in the world, and Candida albicans and Candida parapsilosis are the two most common species.

Objectives

To determine the yeast species frequency and their in vitro antifungal susceptibility test, obtained from patients with clinical features suggestive of onychomycosis.

Methods

A prospective study was carried out in four dermatological care centers in Mexico from 2004 to 2007. Clinical diagnosis was corroborated by direct examination and culture. The yeast species was determined by morphological and biochemical tests. An antifungal susceptibility test to ketoconazole, itraconazole and fluconazole by the broth microdilution method was performed on each isolate (document M27-A2).

Results

One hundred sixty-six yeast isolates were obtained; the most frequently found species were C. parapsilosis (31.9 % ), C. albicans (22.4 % ) and Candida guilliermondii (12.7 % ). Of all isolates, 51 showed resistance to one or several of the azole compounds: 33 to itraconazole, 12 to ketoconazole and 6 to fluconazole. It was remarkable that the four Candida glabrata isolates were resistant to the three azole compounds; C. guilliermondii and Candida famata were resistant to itraconazole in 42.9 % and 54.5 % , respectively.

Conclusion

The results obtained show the importance of identifying the aetiological agent and antifungal susceptibility testing in order to avoid therapeutic failures in onychomycosis.